GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Vanda Pharmaceuticals Inc. (VNDA) [hlAlert]

Rating:
Neutral VNDA
down 93.62 %

Vanda Pharmaceuticals Inc. (VNDA) downgraded to Neutral by Banc of America Sec

Posted on: Tuesday,  Jul 29, 2008  8:25 AM ET by Banc of America Sec

Banc of America Sec rated Neutral Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) on 07/29/2008. Previously Banc of America Sec rated Buy Vanda Pharmaceuticals Inc. (NASDAQ:
VNDA) on 09/10/2007., when the stock price was $14.27. Since then, Vanda Pharmaceuticals Inc. has lost 93.62% as of 07/29/2008's recent price of $0.91.
If you would have followed the previous Banc of America Sec's recommendation on VNDA, you would have lost 93.62% of your investment in 323 days.

Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of clinical-stage product candidates for central nervous system disorders. It is developing important new medicines to improve the lives of patients. It uses new technologies, including genetics & genomics, to inform our drug discovery, our clinical trials, and our commercial positioning of our compounds. The Company has three product candidates in clinical development. It's lead product candidate, iloperidone, is a compound for the treatment of schizophrenia & bipolar disorder & is in a Phase III clinical trial for schizophrenia. It's second product candidate, is a compound for the treatment of insomnia & depression which is currently in a Phase III clinical trial for insomnia. It's third product candidate, is a compound for the treatment of excessive sleepiness & is ready for a Phase II clinical trial.

Integrity, objectivity and originality are cornerstones of the value–added research that we offer to corporate and institutional clients. As thought leaders, our goal is to help clients understand and adapt to changing economic conditions and events that drive markets, currencies, industries and companies worldwide. And we deliver innovative ideas based on rigorous primary research, sound principles and clear vision. Our research teams are organized by areas of expertise, from equities, fixed income and emerging markets to foreign exchange and global financial risk advisory – featuring many of the industry’s most respected analysts and economists. Through our private, password–protected Web portal, our clients have access to a comprehensive array of timely research and commentary, including: * U.S. and global economic updates and indicators * Federal budget and fiscal policy * Industry outlooks * Stock coverage and picks * Financial market strategies * Corporate bond issuer risk analysis
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
7/29/2008 8:25 AM Hold
None
0.91
as of 12/24/2008
1 Week down  -10.47 %
1 Month up  17.50 %
3 Months up  23.68 %
1 YTD up  88.00 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
9/10/2007 9:25 AM Buy
None
14.27

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy